Table 1.
Baseline group characteristics and laboratory of the study population
| Control N=30 | ACS N=99 | Chronic CAD N=85 | P-value | |
|---|---|---|---|---|
| Age, years | 62.9±11.5 | 63.8±11.4 | 62.9±11.5 | 0.09 |
| Female, % | 53.3 | 24.2* | 20* | 0.001 |
| BMI, kg/m2 | 28±4.26 | 28.6±3.8 | 29.2±4 | 0.39 |
| Waist, cm | 97.3±11.2 | 99.8±11.2 | 101.4±10 | 0.18 |
| Hypertension, % | 40 | 59.6 | 49.4 | 0.29 |
| Diabetes mellitus, % | 3.3 | 21.2 | 23.5 | 0.12 |
| Smoking, % | 3.3 | 31.3* | 20* | 0.004 |
| Family history, % | 37.9 | 34.3 | 45.7 | 0.29 |
| Hyperlipidemia, % | 20 | 29.3 | 50.6*,** | 0.001 |
| SBP, mmHg | 125±13 | 125±16 | 125±13 | 0.99 |
| DBP, mmHg | 73±12 | 71±11 | 74±10** | 0.01 |
| Heart rate, beats/min | 73.1±8.2 | 73.5±11.3 | 72.2±12.6 | 0.72 |
| History of MI, % | - | 20.2 | 22.4 | 0.72 |
| History of CABG, % | - | 10.1 | 10.6 | 0.18 |
| ASA, % | 16.7 | 39.4* | 47.1* | 0.01 |
| Clopidogrel, % | - | 17.2 | 14.1 | 0.05 |
| BB, % | 13.3 | 29.3* | 42.4* | 0.01 |
| ACE inhibitor, % | 16.7 | 23.2* | 35.6* | 0.04 |
| Statin, % | 3.3 | 25.3 | 32.9 | 0.06 |
| Spironolactone, % | - | 3 | 4.7 | 0.45 |
| TC, mg/dL | 170±34 | 172±41 | 164±42 | 0.38 |
| TG, mg/dL | 131±71 | 137±70 | 136±60 | 0.66 |
| LDL-C, mg/dL | 120±30 | 126±35 | 118±38 | 0.31 |
| HDL-C, mg/dL | 41.5±10.2 | 36.5±7.5* | 36.2±6.7** | 0.004 |
| sTWEAK, pg/mL | 799±208 | 756±624* | 728±652* | <0.0001 |
| sCD163, ng/mL | 593±212 | 866±282* | 643±28** | <0.0001 |
| sCD163/sTWEAK | 0.8±0.3 | 1.6±0.9* | 1.2±0.6** | <0.0001 |
| CRP, mg/dL | 0.9±1.6 | 1.5±2.6* | 1.2±3.6** | 0.007 |
Data expressed as mean±SD or percentage. Statistical significance was set at p-value <0.05. Bold values indicate significant values (P<0.05). ACE: angiotensin converting enzyme; ASA: acetyl salicylic acid; BB: beta blocker; BMI: body mass index; CRP: C-reactive protein; CABG: coronary artery bypass graft; DB, diastolic blood pressure; HDL-C: high-density lipoprotein-cholesterol; LDL-C: low-density lipoprotein-cholesterol; MI: myocardial infarction; SBP: systolic blood pressure; sCD163: soluble CD163; sTWEAK: soluble tumor necrotizing factor-like weak inducer of apoptosis; TC: total cholesterol; TG: total glyceride.
Significantly different compared to the control group;
Significantly different compared to the ACS group.